TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37076861

Group type: EXPERIMENTAL
Intervention: Carotid Doppler peak velocity (CDPV) during end-expiratory occlusion test (EEOt)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Corrected flow time (cFT) during end-expiratory occlusion test (EEOt)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cardiac index (CI) increase during fluid challenge
Number of subjects: 18
Study: 37076884

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study: 37076883

Group type: EXPERIMENTAL
Intervention: Non-intubated deep paralysis (NIDP)
Number of subjects: 20
Study: 37077305

Group type: EXPERIMENTAL
Intervention: Ophthalmic DMPC-based nanoemulsion (Nanodrop®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37077560

Group type: EXPERIMENTAL
Intervention: Structured kangaroo care education program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine care without structured education program
Number of subjects: 96
Study: 37077705

Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 6-Month (PP6M)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Paliperidone Palmitate 3-Month (PP3M)
Number of subjects: 384
Study: 37077733

Group type: EXPERIMENTAL
Intervention: Major noncardiac surgery in high-altitude areas
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Risk factors for PCCs
Number of subjects: 196
Study: 37077916

Group type: EXPERIMENTAL
Intervention: Golidocitinib (5 - 150 mg single dose; 25 - 100 mg once daily for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golidocitinib (50 mg) under fed conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golidocitinib (25 - 150 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golidocitinib (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37077927

Group type: EXPERIMENTAL
Intervention: Biofilm disrupting acne cream 2x
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofilm disrupting acne cream 1x
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofilm disrupting acne cream without salicylic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5% BPO gel
Number of subjects: 0
Study: 37078004

Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) with concurrent chemotherapy
Number of subjects: 65
Study: 37078188

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Active Control (CTRL) therapy
Number of subjects: 179
Study: 37078412

Group type: EXPERIMENTAL
Intervention: Entospletinib 400 mg twice daily with decitabine 20 mg/m²
Number of subjects: 58
Study: 37078544

Group type: EXPERIMENTAL
Intervention: Counselling with video of endoscopic procedure
Number of subjects: 232

Group type: COMPARATOR
Intervention: Counselling with no-video
Number of subjects: 232
Study: 37078654

Group type: EXPERIMENTAL
Intervention: polydextrose
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: psyllium husk
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: wheat bran + psyllium husk
Number of subjects: 250

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 250
Study: 37078691

Group type: EXPERIMENTAL
Intervention: Any AF event
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: AF on ECG
Number of subjects: 1002
Study: 37078706

Group type: EXPERIMENTAL
Intervention: Orelabrutinib 150 mg once daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Orelabrutinib 100 mg twice daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Orelabrutinib (both doses)
Number of subjects: 106
Study: 37078771

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (3.375 or 4 g intravenously)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Cefoxitin (2 g intravenously; standard care)
Number of subjects: 778
Study: 37078953

Group type: EXPERIMENTAL
Intervention: CIK with gemcitabine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gemcitabine alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CIK alone
Number of subjects: 80
Study: 37078969

Group type: EXPERIMENTAL
Intervention: Goal-focused Emotion-regulation Therapy (GET)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Individual Supportive Listening (ISL)
Number of subjects: 75
Study: 37079108

Group type: EXPERIMENTAL
Intervention: Queckenstedt's test (QT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Repeated Queckenstedt's test (QT)
Number of subjects: 14
Study: 37079106

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 572
Study: 37079305

Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT) - 4 sessions of 20 minutes each, including 40 slip, trip, or mixed perturbations
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Laboratory fall rates post-training assessment
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Laboratory fall rates at 6-month follow-up
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Laboratory fall rates at 12-month follow-up
Number of subjects: 140

Group type: COMPARATOR
Intervention: Daily-life fall rates
Number of subjects: 140

Group type: COMPARATOR
Intervention: Other daily-life fall-related metrics
Number of subjects: 140
Study: 37079324

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with a single dose of 16 or 18 Gy to involved vertebral levels
Number of subjects: 339

Group type: COMPARATOR
Intervention: Conventional external beam radiotherapy (cEBRT) with 8 Gy to involved vertebra plus 1 additional vertebra above and below
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 339

Group type: COMPARATOR
Intervention: cEBRT
Number of subjects: 339
Study: 37079363

Group type: EXPERIMENTAL
Intervention: Mobile Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 30
Study: 37079364

Group type: EXPERIMENTAL
Intervention: AOT at the hospital
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AOT at home
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham AOT
Number of subjects: 60
Study: 37079365

Group type: EXPERIMENTAL
Intervention: Multimodal provider education intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patient activation intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions (provider education and patient activation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: None of the interventions
Number of subjects: 20
Study: 37079367

Group type: EXPERIMENTAL
Intervention: Real-time NLP-driven Clinical Decision Support (CDS) tool for opioid misuse screening
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Best Practice Alert (BPA) for screening results with recommendations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Implementation framework with user feedback
Number of subjects: 100
Study: 37079385

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 205
Study: 37079390

Group type: EXPERIMENTAL
Intervention: StableVisc
Number of subjects: 390

Group type: COMPARATOR
Intervention: ProVisc
Number of subjects: 390
Study: 37079393

Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 37079511

Group type: EXPERIMENTAL
Intervention: CardioMEMS PA Sensors
Number of subjects: 101
Study: 37079518

Group type: EXPERIMENTAL
Intervention: Rare CIDEC coding variants in patients with small LLD.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with small LLD (indicating better prognosis and better anti-VEGF treatment response).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional analysis of CIDEC alleles in vitro.
Number of subjects: 0
Study: 37079569

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies
Number of subjects: 1
Study: 37079651

Group type: EXPERIMENTAL
Intervention: UB-612 booster (third dose)
Number of subjects: 1478
Study: 37079726

Group type: EXPERIMENTAL
Intervention: UST/MTX (Ustekinumab with Methotrexate), n = 58
Number of subjects: 112

Group type: COMPARATOR
Intervention: UST/pbo (Ustekinumab with Placebo), n = 54
Number of subjects: 112

Group type: COMPARATOR
Intervention: UST/pbo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: UST/MTX
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: UST/MTX and UST/pbo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ADA formation
Number of subjects: 112
Study: 37079851

Group type: EXPERIMENTAL
Intervention: Immersive VR environment (VR Blu)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Content control with nonimmersive tablet computer (Tablet Blu)
Number of subjects: 60

Group type: COMPARATOR
Intervention: VR Blank (donning VR headgear without content)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 60
Study: 37079894

Group type: EXPERIMENTAL
Intervention: Rifabutin triple therapy (14-day esomeprazole 20 mg, amoxicillin 1.0 g, rifabutin 150 mg twice a day)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Bismuth quadruple therapy (esomeprazole 20 mg, bismuth 220 mg twice a day, metronidazole 400 mg, tetracycline 500 mg 4 times a day)
Number of subjects: 364
Study: 37079900

Group type: EXPERIMENTAL
Intervention: Pharmacy-based PrEP delivery model
Number of subjects: 287

Group type: COMPARATOR
Intervention: Standardized client actors (mystery shoppers)
Number of subjects: 287
Study: 37080000

Group type: EXPERIMENTAL
Intervention: Single RBC (1-RBC arm)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Double RBC (2-RBC arm)
Number of subjects: 245
Study: 37080222

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 649

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 649
Study: 37080223

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (carboplatin and paclitaxel) after standard cisplatin-based chemoradiotherapy
Number of subjects: 926

Group type: COMPARATOR
Intervention: Chemoradiotherapy only
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (carboplatin and paclitaxel)
Number of subjects: 926
Study: 37080224

Group type: EXPERIMENTAL
Intervention: Pertussis vaccination in group 1 (≤23 weeks + 6 days)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Pertussis vaccination in group 2 (24-27 weeks + 6 days)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Pertussis vaccination in group 3 (28-31 weeks + 6 days)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Pertussis vaccination in all groups
Number of subjects: 364
Study: 37080296

Group type: EXPERIMENTAL
Intervention: Activity restriction (pelvic rest, prohibition of sexual activity, reduction of work and/or nonwork activity)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No activity restriction (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Activity restriction
Number of subjects: 120
Study: 37080354

Group type: EXPERIMENTAL
Intervention: Quitline plus smoke-free homes intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard quitline
Number of subjects: 0
Study: 37080442

Group type: EXPERIMENTAL
Intervention: FB-EVAR
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: FB-EVAR (Group 1 - prior EVAR)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: FB-EVAR (Group 2 - prior abdominal OSR)
Number of subjects: 506

Group type: COMPARATOR
Intervention: FB-EVAR (Controls - no previous aortic repair)
Number of subjects: 506
Study: 37080462

Group type: EXPERIMENTAL
Intervention: 100 mg PP + CC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PP (doses ≤150 mg)
Number of subjects: 50
Study: 37080558

Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography-assessed liver stiffness (LS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 6-point Dixon-derived proton density fat fraction (PDFF)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Single-point saturation-recovery acquisition-calculated T1 relaxation time
Number of subjects: 104
Study: 37080624

Group type: EXPERIMENTAL
Intervention: Screening group (baseline samples immediately analysed for total homocysteine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (baseline samples analysed after 12 months)
Number of subjects: 0
Study: 37080623

Group type: EXPERIMENTAL
Intervention: 0.02% atropine eyedrops
Number of subjects: 300

Group type: COMPARATOR
Intervention: 0.01% atropine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 0.02% atropine
Number of subjects: 300
Study: 37080628

Group type: EXPERIMENTAL
Intervention: Point-of-care testing for six STIs alongside routine HIV and syphilis testing.
Number of subjects: 1000
Study: 37080629

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 200
Study: 37080829

Group type: EXPERIMENTAL
Intervention: Half-dose MVC-COV1901
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Full-dose MVC-COV1901
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: AZD1222
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Half-dose mRNA-1273
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Heterologous boosting (mRNA-1273 in MVC-COV1901 primed individuals)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: MVC-COV1901 as a primary series with either homologous or heterologous booster
Number of subjects: 803
Study: 37080942

Group type: EXPERIMENTAL
Intervention: E7130 administered intravenously at 480 μg/m (Q3W)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: E7130 administered intravenously at 480 μg/m (Q2W)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: E7130 (both Q3W and Q2W)
Number of subjects: 44
Study: 37080946

Group type: EXPERIMENTAL
Intervention: Involvement in KRT decision-making
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Education on KRT and decision aids for relatives/friends
Number of subjects: 56
Study: 37081029

Group type: EXPERIMENTAL
Intervention: Fish oil and evening primrose oil (EPO) supplementation (2 gel capsules of fish oil and 3 gel capsules of EPO for 12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mineral oil (placebo, 5 gel capsules of 1g for 12 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fish oil and evening primrose oil (EPO) supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mineral oil (placebo)
Number of subjects: 32
Study: 37081046

Group type: EXPERIMENTAL
Intervention: Tocilizumab/infliximab with standard treatment
Number of subjects: 153

Group type: COMPARATOR
Intervention: Tocilizumab with standard treatment
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 153
Study: 37081093

Group type: EXPERIMENTAL
Intervention: STEP-COVID intervention (six-session mentalization-based prenatal group program offered online)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Natural trajectory of prenatal care (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: STEP-COVID intervention
Number of subjects: 100
Study: 37081278

Group type: EXPERIMENTAL
Intervention: Micronised purified flavonoid fraction
Number of subjects: 6000
Study: 37081406

Group type: EXPERIMENTAL
Intervention: Intensive Neurophysiological Rehabilitation System (INRS) treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (waiting list for 4 weeks, then INRS treatment)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: INRS treatment
Number of subjects: 48
Study: 37081426

Group type: EXPERIMENTAL
Intervention: Intravenous Lutetium-177 PSMA Radioligand Therapy (RLT) followed by one fraction of HDR brachytherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: High dose rate (HDR) brachytherapy in two fractions (standard of care salvage treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lutetium-177 PSMA RLT and HDR brachytherapy
Number of subjects: 30
Study: 37081460

Group type: EXPERIMENTAL
Intervention: Active Living Every Day (ALED) intervention
Number of subjects: 336

Group type: COMPARATOR
Intervention: Supervised exercise sessions, facility access, Fitbit self-monitoring
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 336
Study: 37081459

Group type: EXPERIMENTAL
Intervention: RBS after AGB (types included sleeve gastrectomies, Roux-en Y gastric by-passes, one anastomosis gastric by-passes)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: RBS after AGB
Number of subjects: 234
Study: 37081474

Group type: EXPERIMENTAL
Intervention: Mechanical power (MP) on hospital day 1 (HD1)
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Mechanical power (MP) on hospital day 3 (HD3)
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Mechanical power (MP) on hospital day 7 (HD7)
Number of subjects: 1217
Study: 37081523

Group type: EXPERIMENTAL
Intervention: Aneuploidy in Circulating Tumour DNA (ACT-Discover) method using haplotype phasing of paired tumour biopsies or PDXs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patient-derived xenograft (PDX) tumours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ACT-Discover method
Number of subjects: 24
Study: 37081524

Group type: EXPERIMENTAL
Intervention: Mixed oil (MO) lipid emulsion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Soybean oil (SO) lipid emulsion
Number of subjects: 60
Study: 37081528

Group type: EXPERIMENTAL
Intervention: Convolutional neural network classifier for Alzheimer's disease detection
Number of subjects: 432
Study: 37081534

Group type: EXPERIMENTAL
Intervention: Suubi intervention components (Financial Literacy Training, incentivized matched Youth Savings Accounts, manualized ART adherence intervention, engagement with role models)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Combination of Suubi intervention components
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Assessments at baseline, 12, 24, 36, and 48 months post-intervention initiation
Number of subjects: 576
Study: 37081574

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg once weekly
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 37081617

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Reduced eGFR
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Elevated urinary albumin-to-creatinine ratio
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Guideline-recommended treatment (ACE inhibitors, ARBs)
Number of subjects: 2424
Study: 37081722

Group type: EXPERIMENTAL
Intervention: Pyrotinib (400 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus docetaxel (60 mg)
Number of subjects: 25
Study: 37082098

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks (Q3W)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Chemotherapy (platinum-doublet)
Number of subjects: 563
Study: 37082579

Group type: EXPERIMENTAL
Intervention: TRK-950 (therapeutic humanized anti-CAPRIN-1 antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRK-950
Number of subjects: 0
Study: 37082807

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20000
Study: 37082935

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37082967

Group type: EXPERIMENTAL
Intervention: Intravenous nerinetide
Number of subjects: 1092
Study: 37083029

Group type: EXPERIMENTAL
Intervention: Person-centered care (PCC) intervention for inpatient staff
Number of subjects: 0
Study: 37083300

Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy (BMX)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-BMX treatments
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: BC patients
Number of subjects: 123

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 123
Study: 37083317

Group type: EXPERIMENTAL
Intervention: Proactive CHW delivery (door-to-door home visits)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Passive CHW delivery (fixed village site)
Number of subjects: 137
Study: 37083360

Group type: EXPERIMENTAL
Intervention: Novel kit formulation targeting fibroblast activation protein (FAP)
Number of subjects: 0
Study: 37083403

Group type: EXPERIMENTAL
Intervention: Gut Microbiota
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum Metabolites
Number of subjects: 0
Study: 37083461

Group type: EXPERIMENTAL
Intervention: Mixed nuts (42g daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Potato chips (46g daily)
Number of subjects: 20
Study: 37083464

Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Client Violence
Number of subjects: 400
Study: 37083664

Group type: EXPERIMENTAL
Intervention: Esketamine (0.25 mg/kg intravenous injection)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Esketamine and Placebo
Number of subjects: 903
Study: 37083700

Group type: EXPERIMENTAL
Intervention: Community-based, peer-led sexual and reproductive health services (Yathu Yathu intervention)
Number of subjects: 1989

Group type: COMPARATOR
Intervention: Control arm (health facility only)
Number of subjects: 1989
Study: 37083738

Group type: EXPERIMENTAL
Intervention: Pectoserratus plane block (PSPB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study: 37083754

Group type: EXPERIMENTAL
Intervention: MedViewer test
Number of subjects: 36
Study: 37084097

Group type: EXPERIMENTAL
Intervention: Passive breaks (2.5-min standing rest)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Active breaks (2.5-min targeted stretching and mobilization exercises)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No breaks (control condition)
Number of subjects: 21